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Abstract 
Background: Recent advances in the development of small chemical compounds that can modulate RNA splic-
ing brought excitement to the field of splicing-targeting therapy. Splicing-targeting therapy tries to ameliorate the 
disease by altering the exon combination of transcripts to reduce the undesired effect of genetic mutations. However, 
the knowledge and tools to understand factors contributing to splicing modulator compound sensitivity have been 
lacking. Our goal was to establish a method to characterize sequence features found in compound sensitive exons.
Results: Here we developed a comparative transcriptomic approach to explore features that make an exon sensitive to 
a chemical compound. In this study, we chose TG003, a potential drug for Duchenne muscular dystrophy, and performed 
RNA-sequencing on samples from human and mouse skeletal muscle cells, with and without TG003 treatments. We 
compared TG003 responsiveness between homologous exon pairs and identified 21 pairs in which human exons were 
skip-enhanced but not mouse exons. We compared the sequence features; splice site scores, number of splicing factor 
binding sites, and properties of branch sequence and polypyrimidine tracts, and found that polypyrimidine tracts were 
stronger (longer stretches and richer content of consecutive polypyrimidine) in the mouse TG003 insensitive exons. We 
also compared the features between TG003 skip-enhanced and insensitive exons within the species, and discovered that 
human TG003 skip-enhanced exons were shorter and had less splicing factor binding sites than the group of human 
TG003 insensitive exons. Mouse insensitive exons homologous to human TG003 skip-enhanced exons shared these 
properties. Our results suggested that these features are prerequisites for TG003 skip-enhanced exons and weak polypy-
rimidine tracts are defining features, which were supported by a decision tree analysis on all cassette exons in human.
Conclusions: In this study we established a comparative transcriptomic approach, which shed lights on how small 
chemical compounds modulate RNA splicing. The results described here was the first attempt to decipher the target-
ing rules of a splicing modulator compound. We expect that this approach would contribute to the precise under-
standing of the mechanism of TG003-induced splicing modulation, expand target diseases of splicing modulators in 
general, as well as the development of new splicing modulators.
Keywords: Comparative pharmacogenomics, Comparative transcriptomics, Virtual massive mutagenesis, RNA-
targeting therapy, Personalized medicine, Splicing modulator, Polypyrimidine tract, Duchenne muscular dystrophy
© 2015 Sakuma et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Mammalian gene expression requires the accurate exci-
sion of introns and ligation of exons from the pre-mRNA 
by splicing, and approximately 95  % multi-exon genes 
undergo alternative splicing in human [1]. Alternative 
splicing contributes to proteomic diversity and organ-
ismal complexity because isoforms can have different 
functions or have non-functional forms to fine-tune the 
regulation and expression levels of one gene product.
Splicing has been a target of therapy for diseases [2–4]. 
There are genetic diseases with mutations located near 
splice sites that cause abnormal splicing such as familial 
dysautonomia. In this case, a mutation occurred 6 base 
downstream from exon 20 of IKBKAP gene inhibits inclu-
sion of the exon. Attempts have been made to increase 
the inclusion of the exon by chemical compounds such as 
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kinetin and RECTAS [5, 6]. There are also diseases that 
may not have mutations at splice sites, but can be cured 
by interfering with the splicing process. For example, in 
order to compensate for the loss of the functional SMN1 
gene, the therapy of Spinal Muscular Atrophy intends to 
increase the expression of SMN2 gene by enhancing the 
inclusion of a normally skipped exon 7, which is neces-
sary to produce a functional transcript of SMN2 gene [7]. 
Another example is one of the therapy strategies of Duch-
enne muscular dystrophy (DMD), which is to induce the 
skipping of exons mutated to be poison exons in the dys-
trophin gene [8]. Other possible target disorders of this 
exon-skipping strategy include pseudo-exon diseases [9], 
which are diseases caused by an emergence of an exon in 
the intronic regions due to genetic mutations that create 
a de novo splice site.
Our group developed TG003, a specific CLK (cdc2-
like kinase) family inhibitor (CLK1, 2, 4) [10], and iden-
tified that TG003 was able to increase the skipping of a 
mutated exon 31 of the dystrophin gene, and increased 
the expression of this gene at the protein level [11]. 
This study opened the possibility of treatment of DMD 
with TG003, and we further identified a patient whose 
mutated exon 27 can be enhanced skipping by TG003, 
whereas none of the wild type exons are affected by 
TG003 [11]. Advance in knowledge of the features pre-
sent in TG003 sensitive exons would be very useful for 
application in personalized subscription of splicing 
modulators, but this has been obstructed by the intricate 
mechanism of splicing and the fact that TG003 targets 
RNA indirectly. The direct targets of TG003 are CLKs, 
which phosphorylate SR proteins [12–15]. They have 
different RNA target sequences [16, 17], and the precise 
rules of how phosphorylation and dephosphorylation of 
multiple SR proteins affect splice site selection has not 
been clarified yet [18–20].
In this study we set out to find a rule that can help us 
understand which exons will be affected by TG003 treat-
ment. Recently, Barbosa-Morais et al. [21] suggested that 
the outcome of splicing events is determined more by 
the cis-elements (sequence) than the trans-environment 
(the set of RNA binding factors in the cell), performing 
cross-species experiments with human and mouse. This 
prompted us to design a comparative transcriptome 
analysis of human and mouse to identify sequence fea-
tures that make exons responsive to TG003. Compara-
tive studies in human and mouse produced many fruitful 
results in splicing [22, 23] suggesting that these genomes 
are similar enough, but at the same time we know that 
there are many sequence variations. We focused on this 
difference between the genomes to understand what 
kind of variations in sequence would gain or lose the 
response to TG003, assuming that the responses to an 
artificial product by different organisms are probably not 
conserved.
In this study we performed RNA-sequencing (RNA-
seq) to evaluate the response to TG003 in human and 
murine skeletal muscle cells. We observed that the gen-
eral response to TG003 in terms of direction and scope 
in human and mouse is similar, likely to reflect the fact 
that the trans-factors that TG003 interferes with are 
conserved. However we found multiple exons with high 
sequence similarity but different response to TG003 
between human and mouse. Assuming that the differ-
ence in response may originate from slight differences in 
the splicing cis-elements, we proceeded to characterizing 
sequence features, and found that TG003-sensitive exons 




In order to investigate the TG003 sensitive exons in the 
two species, we performed RNA-seq on human skeletal 
muscle cells (hSkMC) and mouse C2C12 cells treated 
with 20 μM of TG003 or no treatment (0.4 % DMSO) for 
4 h. The numbers of mapped reads and mapping rates are 
summarized in Additional file  1: Table S1. To quantify 
the change in splicing, we calculated Δψ, which stands 
for difference (Δ) in Percent Spliced In (ψ), and measures 
the difference in the inclusion rates (ψ) between the two 
conditions (see methods). In order to confirm the effect 
of TG003, we looked at CLK1 and CLK4 exon 4, which 
we have consistently observed response to TG003 in dif-
ferent types of cells [10, 15]. RNA-seq reproduced the 
effect of TG003 in CLKs in our samples as did RT-PCR 
(Fig. 1a drawn in sashimi-plot [24], Additional file 2: Fig-
ure S1).
TG003 is a splicing modulator with an orientation to skip 
enhancement both in human and mouse
Next we tried to characterize the effect of TG003 to alter-
native exon-skipping events in general. We calculated the 
Δψ values for all 37287 and 11891 annotated alterna-
tive exon-skipping events in human and mouse Ensembl 
database, respectively. We observed a slight negative shift 
in the distribution of Δψ values compared to the base-
line fluctuation of Δψ values (Δψ between replicates), 
both in human and mouse, indicating that TG003 is a 
general skip enhancer, and the ratio of skip-enhanced 
(Δψ  ≤  −0.05) to inclusion-enhanced (Δψ  ≥  0.05) was 
remarkably similar between human and mouse (Fig. 1b).
We next investigated the conservation of response 
to TG003 at the level of individual alternative exon-
skipping events. To determine this we made a sub-
set of 2988 sequence-conserved exon-skipping 
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Fig. 1 TG003 is a general skip enhancer both in human and mouse. a RNA-seq data identifies splicing changes in formerly known TG003 sensitive 
exons. RNA-seq data was inputted to sashimi-plot for graphical representations. Numbers of junction reads calculated by our method are shown at 
the junction position. The black boxes below represent the exons and the arrows indicate the direction of transcription. ψ and Δψ values are calcu-
lated on the right. b Left histogram of the average Δψ values [Δψavg = (ΨDMSO.rep1 − ΨTG003.rep1 + ΨTG003.rep2 − ΨDMSO.rep2)/2)] of all annotated exon-
skipping exons are shown in green for human and yellow for mouse. The distribution of difference in ψ between replicates of the same condition 
are shown in black to show the average baseline fluctuation of ψ values [(ΨDMSO.rep1 − ΨDMSO.rep2 + ΨTG003.rep1 − ΨTG003.rep2)/2]. The black dashed 
line shows the cutoff value of Δψ = −0.05 for skip and Δψ = 0.05 for inclusion. Right pie chart of the ratio of skip-enhanced (Δψavg ≤ −0.05) and 
inclusion-enhanced (Δψavg ≥ 0.05) exons. c Venn diagram of the overlap between the number of human and mouse annotated exon-skipping 
events in Ensembl. d Distribution of 1145 expressed and consistent conserved annotated exon-skipping events in both species into the nine 
categories. Circles roughly show the scales, and the numbers show the exact counts. Numbers in the brackets show the expected values for each 
categories under the assumption of no-conservation of TG003 effects between the species
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events from all the annotated exon-skipping events 
in human and mouse (Fig.  1c). These events had on 
average 93.6  % sequence similarity over 98.5  % of the 
exonic region. We took 1995 events that had sufficient 
expression in both species and filtered out events that 
had inconsistent TG003 effects between two repli-
cates in either of the species, which left us with 1145 
events. For each event, we classified events into skip 
(Δψ  ≤  −0.05), inclusion (Δψ  ≥  0.05) and no effect 
(−0.05  <  Δψ  <  0.05) for human and mouse respec-
tively, and grouped each event into one of the nine cat-
egories as shown in Fig.  1d. The number of events in 
the categories that have exons with conserved response 
to TG003; “human-skip mouse-skip”, “human-inclusion 
mouse-inclusion”, and “human-no effect mouse-no 
effect”, were higher than expectation values which were 
calculated under the assumption that there is no con-
servation of TG003 effects. The differences between 
observed values and expectation values were significant 
with Chi square test (p < 2.2e−16).
Virtual massive mutagenesis mimicked 
by species‑comparing transcriptomic analysis
The previous results showed that the general response to 
TG003 is conserved, possibly reflecting the fact that the 
trans-factors that TG003 works through is generally con-
served, but there were several exons that did not respond 
in the same manner (Fig. 1d). In order to find the rules 
that make an exon responsive to TG003, these pairs of 
exons would be most informative because they respond 
differently though there is only small differences in the 
sequence.
We focused our attention on human skip-enhanced 
splicing events and expanded our comparison set to all 
possible internal mouse exons. The schematic of the 
analysis is shown in Fig. 2. We first constructed a set of 
human skip-enhanced splicing event set with stricter 
criteria. We ensured that the level of gene and junction 
expression are sufficiently high, and obtained splicing 
events with Δψ ≤ −0.25 that also passed t test with p 
value  <0.05. This left us with 110 human TG003 skip-
enhanced splicing events as our starting set. We searched 
for homologous exons in all internal mouse exons, and 
obtained 45 human skip-enhanced splicing events with 
mouse homologous exons. We calculated the Δψ val-
ues for the mouse internal exons (they included anno-
tated and unannotated exon-skipping event), and the 
distribution of the Δψ values of these pairs of splicing 
events are shown in Fig.  3a (Ensembl IDs and Δψ val-
ues are summarized in Additional file  3: Table S2). We 
grouped the mouse splicing events depending on their 
response to TG003 as shown in Fig.  3b. We confirmed 
the RNA-seq data of the representative cases by RT-PCR 
(Fig.  3c), which reproduced the response to TG003 as 
was observed by the RNA-seq data (Fig.  3d). We also 
confirmed representative cases by RT-PCR from the 
group of exons which were skip-enhanced in both spe-
cies (Fig. 3b, red fraction) by TG003 as well as the group 
of exons which were skip-enhanced only in the mouse 
events identified in a separate analysis (Additional file 4: 
Figure S2). 
In order to examine our hypothesis that the differen-
tial results were obtained due to changes in cis-element, 
and not trans-environment we selected DENND4C from 
the group and cloned the human DENND4C (Ensembl: 
ENST00000494124) exon 26–28 and mouse Dennd4c 
(Ensembl: ENSMUST00000142837) exon 29–31, and 
cross-species transfected the minigene reporter. The 
results showed that human DENND4c exon 27 were 
skip-enhanced even in the mouse trans-environment of 
C2C12 cells, when the mouse endogenous Dennd4c did 
not respond to TG003 (Fig.  4, right). Mouse Dennd4c 
exon 30 did not respond to TG003 in the human 
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Fig. 2 Schematic of species-comparing transcriptome analysis. Flow 
chart of the process determining human TG003 skip-enhanced exons 
and its counterpart mouse homologous exons. Squares represent 
public annotations, rounded squares represent our RNA-seq data, oval 
circles represent manipulations. Dark gray squares with cut sides show 
that there was a filtering process. Numbers on the side indicate how 
many events were left after the manipulations
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endogenous DENND4C exon 30 were skip-enhanced by 
the treatment of TG003 (Fig.  4, left). These results sug-
gested that the difference in response to TG003 origi-
nates in the difference in sequences.
Polypyrimidine tract tends to be weaker in TG003 
skip‑enhanced exons
We then tried to identify the sequence features that 



























































































































































Fig. 3 Distribution of Δψ values of human TG003 skip enhanced exons and mouse counterpart homologous exons. a Scatter plot of the Δψ 
values in the two replicates of human TG003 skip-enhanced exons (left) and their counterpart mouse homologous exons (right). b Pie chart 
of the grouping of mouse counterpart homologous exons; skip (Δψ ≤ −0.05 in either of the replicates and Δψ < 0 in the other), no change 
(−0.05 < Δψ < 0.05 in both replicates), inclusion (Δψ ≥ 0.05 in either of the replicates and Δψ > 0 in the other), and others. Others include: no 
expression (Δψ not calculated because there was no junction read), inconsistent [(Δψ ≥ 0.05 and Δ ψ ≤ 0) or (Δψ ≤ −0.05 and Δψ ≥ 0)] occur 
at the same time in the two replicates, psi too low (ψ < 0.05), which never provide Δψ ≥ 0.05. c Experimental validation by RT-PCR of the two 
representative cases of the 21 pairs, that is, SYNRG (Ensembl: ENST00000585472.E20, Ensembl: ENSMUST00000183456.E22) DENND4C (Ensembl: 
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Fig. 4 Difference in response to TG003 is derived from difference in sequence and not trans-environment. Left RT-PCR of endogenous mouse 
Dennd4c exons 28–31 and transfected human DENND4C exons 26–29 in pEGFPc1-human-DENND4c-e29–31 transfected C2C12 cells. Right RT-PCR 
of endogenous human DENND4C exons 25–29 and transfected mouse Dennd4c exons 29–31 in pEGFPc1-human-DENND4c-e29–31 HEK293 cells. 
After transfection both experiments were treated with 50 µM of TG003 for 4 h before harvest
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constructed a set of all homologous pairs of exons that 
were both insensitive to TG003 as a control, and did the 
following comparisons. (A) Comparison between human 
TG003 skip-enhanced exons and mouse homologous 
TG003 insensitive exons that were identified in the previ-
ous section. (B) Comparison between the control set of 
homologous human and mouse TG003 insensitive exons 
if there were any significant differences in comparison A. 
(C) Comparison between human skip-enhanced exons 
used in A and human insensitive exons used in B. (D) 
Comparison between mouse insensitive exons used in 
A and mouse insensitive exons used in B. We expected 
that the four comparisons together would reveal the true 
determinants of TG003 response. We quantified the fol-
lowing features for every exon; exon length, number of 
ESEs (exonic splicing enhancers), number of ESSs (exonic 
splicing silencers), strength of 5′ splice site and 3′ splice 
site (branch sequence, polypyrimidine tract, 3′ splice 
site), intron length, 5′ splice site of upstream introns and 
3′ splice site of downstream introns, which are known as 
contributing factors for the outcome of splicing [25–28].
Figure  5 shows the distribution of scores of the four 
groups of exons in box plots, and values used are sum-
marized in Additional file  5: Table S3, Additional file  6: 
Table S4, and graphical representations of upstream 

















































Exon Length Number of ESEs Number of ESSs
MaxEntScan 3’ss scoreMaxEntScan 5’ss score Branch Sequence Score Pyrimidine Tract Score
1 2 3 4 1 2 3 4 1 2 3 4
1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4
1: control human
2: homologous control mouse
3: TG003 skip-enhanced human 











MaxEntScan 5’ss score Upstream Intron Length Downstream Intron Length
*
Fig. 5 Sequence features comparisons between different exon sets identify characteristics of TG003 skip-enhanced exons. Box plots of scores of 
sequence features of control homologous exon pairs (n = 2335) and human TG003 skip-enhanced and their insensitive mouse counterpart exon 
pairs (n = 21). Median is shown by bold horizontal line and boxes are drawn between the third quartile (top of box) and first quartile (bottom of 
box). Outliers are either three times interquartile range or more above the third quartile, or three times interquartile range or more below the first 
quartile, and are not shown in the plot. The maximum and minimum are shown with the whiskers. (*) indicates p value <0.05, and (**) p value <0.01, 
(***) p value <0.001, calculated by Wilcoxon rank sum test
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were two notable types of features. One type of the fea-
ture is that the feature scores are significantly different 
in both comparison C and D; found in the comparisons 
of exon length, number of ESEs, number of ESSs. The 
other is that the feature scores are significantly different 
in comparison A but not in B; found in the comparison of 
polypyrimidine tract score.
As to the first type of features, the results from com-
parison C suggest that short exon length, few number of 
ESEs and few number of ESSs are important prerequi-
sites for exons to be responsive to TG003, but the results 
from comparison D show that the features are present in 
TG003 insensitive exons, suggesting that these features 
are not sufficient for an exon to be responsive to TG003.
The second type of feature, which showed significant 
difference in comparison A is what seemed to be the 
determinant of TG003 response, that is, “weak” polypy-
rimidine tract. The fact that there was no significant dif-
ference from comparison B suggests that this difference 
is not due to species difference. However the fact that 
there was no significant difference in comparison C sug-
gests that weak polypyrimidine tract is not a determining 
factor in every exon, but likely becomes a determining 
factor in exons which are short and have few splicing fac-
tor binding. We also observed that the insensitive mouse 
exons that are homologous to human exons have sig-
nificantly stronger polypyrimidine tract (comparison D), 
which seems to suggest that short exons with few splic-
ing binding sites are likely targets of TG003 as long as the 
polypyrimidine tract is not too strong.
In addition, we noticed that downstream introns were 
significantly longer in TG003 insensitive exons that were 
homologous to human TG003 skip-enhanced exons than 
in the control TG003 insensitive exons (comparison D). 
However, there was no tendency for human TG003 skip-
enhanced exons to be shorter than human control TG003 
insensitive exons (comparison C).
Box plots of homologous exon pairs that are both skip-
enhanced by TG003 show similar tendency, and impor-
tantly polypyrimidine tract is not strong compared to 
those of their human homologous counterpart exons 
(Additional file 8: Figure S4).
Skip‑enhanced exons are enriched within the groups 
of exons that have weak polypyrimidine tracts and few 
splicing factor bindings
In the previous section we observed that human exons 
that are skipped by TG003 are short and have few num-
ber of splicing factor binding, and among those, we 
found that polypyrimidine tract strength is critical in 
the decision by the splicing machinery whether to skip 
the exon or not. In order to confirm that this trend holds 
for human exons that are not necessarily homologous to 
mouse exons, we focused on all 20897 human annotated 
exon-skipping events that were sufficiently expressed 
and assigned sequence feature scores. We grouped exons 
depending on the length, number of positive and nega-
tive splicing factor binding sites, and polypyrimidine 
tract score, and observed the distribution of the 110 
skip-enhanced events (Δψ ≤ −0.25) by TG003 that we 
defined previously (Fig. 2). The detailed results are sum-
marized in Additional file  9: Table S5. In the groups of 
short exons with few splicing factor binding sites, we 
observed a clear trend that groups of exons with weaker 
polypyrimidine tract are more enriched with TG003 
skip-enhanced exons (region a in Fig. 6a). Especially for 
the group of “Exon length < 65, ESS < 20, ESE < 5”, strong 
association between low polypyrimidine tract scores and 
high enrichment of TG003 skip-enhanced exons were 
observed (Fig.  6b, upper panel). These properties were 
weakened in a group with exons with relatively large 
numbers of ESE sites; 5 ≤ ESE < 16 (Fig. 6b, lower panel). 
These graphs also suggested that too weak polypyrimi-
dine tract (polypyrimidine tract score  <  10) makes the 
exons TG003 insensitive rather than skip-enhanced. We 
also observed enrichment in groups of exons with strong 
polypyrimidine tracts in short exons with high number of 
ESSs (region b in Fig. 6a), which suggests that for exons 
that do not satisfy all of the characteristics (short exon 
length AND few ESE AND few ESS), other rules remain 
to be discovered.
Discussion
In this study we found some rules that can help us under-
stand which exons will be affected by TG003 by a com-
parative transcriptomic analysis approach. We showed 
that TG003 skip-enhanced exons are short exons with 
few splicing factor binding sites and have weak polypy-
rimidine tracts. TG003 is a CLK family inhibitor and 
is known that CLK1 phosphorylates the SR proteins 
[12–15] and phosphorylated SR proteins are known to 
enhance exon inclusion by binding to exonic elements 
[18]. Therefore the fact that TG003 skip-enhanced exons 
have few ESEs is at first counterintuitive. However recent 
research [16] suggests that SR proteins work synergisti-
cally and competitively, and it is more reasonable that 
the effect of TG003 is more dramatic on exons that have 
fewer opportunities for compensatory activity by other 
factors that enhance exon inclusion.
The polypyrimidine tract is rich with pyrimidine 
nucleotides, especially uracil, located about 5–40 base 
pairs before the 3′ end of the intron to be spliced, and 
associates with many protein factors such as the U2 
small nuclear RNA auxiliary factor 2 (U2AF65) and 
polypyrimidine tract-binding protein (PTB). We found 
that the polypyrimidine tract strength is one of the key 
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determinants of TG003 action, which agrees well with 
past research that showed splicing enhancers stimulated 
U2AF65 recruitment to pre-mRNA with weak splice 
sites [29]. When the polypyrimidine tract is rather weak 
for the binding of U2AF65, the exon depends more on 
the splicing factors binding to the ESE, and the inhibi-
tion of SR proteins by TG003 results in exon skipping 
(summarized in Fig. 7). To further explore the possibil-
ity that weak U2AF65 binding to the polypyrimidine 
tract is mediating the exon skipping effect of TG003, 
we compared splicing changes in U2AF65 knock down 
(KD) cells and our TG003 treated cells. The RNA-seq 
data of U2AF65 KD cells was obtained by Shao et  al. 
and was deposited in NCBI SRA with accession number 
SRR1582594 [28]. We listed commonly expressed genes 
among the U2AF65 KD dataset and our current data-
set, and took the overlap of the skip-enhanced exons of 
the commonly expressed genes in the two dataset. We 
obtained 373 exons which were skip-enhanced by both 
TG003 treatments and U2AF65 KD (Additional file 10: 
Table S6). This number was almost twice larger than 
the expected value: 188, which was calculated under 
the assumption that effects of TG003-treatment and 
U2AF65 KD were independent. This difference was 
statistically significant (p  <  2.2e−16) with Chi square 
test. The fact that U2AF65 KD and TG003 treatment 
enhance skipping of a similar set of exons supports 
our hypothesis that TG003 affects exon-skipping via 
changes of interaction between U2AF65 and polypy-
rimidine tract.
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Fig. 6 Groups with weak polypyrimidine tracts are more enriched with TG003 skip-enhanced exons. a Decision tree model of TG003 skip-enhanced 
exons. Boxes are colored according to their enrichment level with the color code shown at the bottom. b Bar graph of enrichment in the four groups 
of polypyrimidine tract strength in exons with short (length <65 nt), few splicing factor binding (ESE < 5 or 5 ≤ ESE < 16, ESS < 20). (*) indicates p 
value <0.05, and (**) p value <0.01, (***) p value <0.001, calculated by hypergeometric test
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Besides, the mutation found in the Duchenne patient, 
who was sensitive to TG003, was located in an ESE of 
exon 31 of Dystrophin gene, which has a weak polypy-
rimidine tract, as we previously reported [11]. When we 
strengthened the polypyrimidine tract of the mutated 
exon 31, the skip-enhancing effect of TG003 was weak-
ened (Kataoka et al. unpublished data).
In evolutionary terms, treatment to artificial products 
such as TG003 is an event that has never occurred in the 
history of evolution and so it is no surprise that evolu-
tion did not prepare different organisms to act in the 
most fitted way to small chemical compounds. Also the 
combinatorial nature and functional redundancy of splic-
ing factors may have permitted wild sequence variation 
through evolution while still preserving the same splic-
ing outcome. This brings an important point to strate-
gies in developing drugs, which is that mouse models and 
murine cells may not be the best model for splicing drug 
analysis. Paying attention to intronic sequence as well 
as the exonic sequences is important even if the default 
splicing pattern is the same.
Identifying target sequences of chemical compounds 
that interfere with splicing is difficult. In contrast to 
RNA-binding proteins, where methods such as HITS-
CLIP (High-throughput sequencing of RNA isolated by 
crosslinking immunoprecipitation) offer a reliable way 
to identify binding sequences of the protein of interest, 
there is no tangible way to “clip” out the target sequence 
of a chemical compound such as TG003 that mildly 
affects many key splicing regulators. However, our com-
parative transcriptomic approach successfully identified 
key factors which determine the sensitivity to TG003. 
We obtained this result through sequence analysis and 
did not need to go through extensive characterization 
of TG003 target proteins. Although more research is 
needed to precisely predict the target exons of TG003 
by sequence inspection, our method proved to bring 
insight into the features of target sequence of compounds 
without prior knowledge of the target proteins of the 
compound.
Conclusions
We used a comparative transcriptomics analysis 
approach to identify sequence features which lead exons 
to be skip-enhanced and shed light on the mechanism of 
TG003 splicing modulation (Fig.  7). Our work contrib-
utes to the field of developing splicing drugs by bringing 
in this method as well as by calling attention to the fact 
that splicing events of different species respond differ-
ently to compounds even if the default splicing pattern 
is similar and exonic sequence conserved. Our approach 
is applicable to other splicing modulators and compari-
son with more than two species may enable examining 
even finer details of the target sequence features. Learn-
ing the target sequences of each splicing drug is useful 
since many patients who have mutations that can benefit 
from splice-modulation do not have the same mutation. 
For example, Nishida et  al. [11] identified two patients 
of DMD whom may benefit from TG003, and these two 
patients had different mutations in different exons, and 
there may be more patients who we do not know yet that 
TG003 may be able to help. Characterization of the target 
sequences of multiple splicing modulators would enable 
offering customized splicing drugs to patients whose 
desired splicing modulations may differ in each case.
Methods
Cell culture and plasmid transfection
Human skeletal muscle cells (hSkMC) and C2C12 myo-
blast cells were maintained in DMEM, supplemented 
with 10  % FBS. Both cells were differentiated at  around 
80 % confluence by switching medium to DMEM supple-
mented with 0.5 % FBS. They were allowed to differenti-
ate for 10 days, by which point fusion of myoblasts with 
multinucleated syncytia were observed. Then cells were 
treated with either 0.04  % DMSO or 20  µM TG003 for 
4 h.
For plasmid transfection we used undifferentiated 
C2C12, HEK293 cells maintained in DMEM, supple-
mented with 10  % FBS. HSkMCs were not used due to 
low transfection efficiency. 2 µg of plasmids were trans-
fected with Lipofectamine 2000 to cells cultured in 6-well 
dishes following standard procedures. Cells were treated 
with DMSO or 50 µM of TG003 4 h before harvest.
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Fig. 7 Model of mechanism of TG003 exon skip enhancement. 
Model of mechanism of TG003 exon skip-enhancement. We showed 
that TG003 skip-enhanced exons have weak polypyrimidine tract, 
which is known to be bound by U2AF65. Some exons require support 
from other splicing factors for splicing reaction. Treatment of TG003 
might result in exon skipping by the loss of the support
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Plasmid constructions
To construct human DENND4C exons 26-29 and mouse 
Dennd4c exons 29-31 splicing reporter, we PCR ampli-
fied the triplet of exons including the flanking introns 
from Human reference DNA male (Catalog #5190-4370, 
Lot #0006139685 Agilent) for human reporter and B6 
mouse genome for mouse reporter. We used XhoI/
BamH1 sites for human amplified segment insertion and 
BglII/SalI sites for mouse amplified segment insertion to 
the pEGFPc1 vector (Clonetech). Primers used are sum-
marized in Additional file 11: Table S7. The internal exon 
and each flanking 100  bp intronic regions were verified 
by sequencing.
RNA extraction, RNA‑seq library preparation, RT‑PCR
Total RNA was extracted from hSkMC and C2C12 cells 
with Sepasol (Nacalai Tesque). 5  µg of total RNA was 
poly-A purified by ambion Dynabeads mRNA DIRECT 
Micro Kit (Life Technologies), and 45 ng of poly-A puri-
fied RNA were used for RNA-seq library preparation 
using Ion Total RNA-seq Kit v2 (Life Technologies). 
Single-end sequencing was performed on Ion Proton 
System.
Reverse transcription was done by Prime Script 
(TaKaRa) with polyT primers, and PCR was done with 
ExTaq (TaKaRa) following the manufacture’s protocol. 
PCR conditions were a cycle of 94 °C for 2 min followed 
by 35 cycles of 98 °C for 10 s, 55 °C for 30 s, and exten-
sion time depending on the length of the transcript. 
The primers used are summarized in Additional file 11: 
Table S7.
RNA‑seq analysis
In order to ensure read quality, we discarded reads 
below 100 nt or 17 of average Phred quality score. We 
used Tophat 2 [30] with options—no-coverage-search—
library-type fr-second strand to map the sequenced 
reads to the Ensembl reference genome with assem-
blies GRCh37.75 for human and GRCm38.75 for mouse 
[31]. When calculating junction reads, we filtered out 
reads which do not extend 8 nt into either of the flank-
ing exons, following the method of Barbosa-Morais et al. 
[21]. The gene expression levels and junction expression 
levels were calculated in reads per kilo-base per million 
reads (RPKM), which is a method to compare the num-
ber of reads across different samples. We quantified the 
reads per kilo-base per 30 million (RPK30  M) to get a 
better resolution. Exon-skipping events were not used 
in the analyses if the gene which the event is on has 
expression less than 16 RPK30M in all of the replicates 
or the total of consecutive three junction reads less than 
4 RPK30M in any of the replicates in at least one of the 
conditions. Analyses using all mouse internal exon set 
did not use this expression filter (sequence feature com-
parison section).
Retrieval of annotated exon‑skipping event
We extracted exon-skipping events from Ensembl anno-
tations [31]. We defined exon-skipping events with the 
alternative exon and the two flanking introns (Additional 
file  12: Figure S5A). In the exon-skipping event extrac-
tion algorithm from the Ensembl database, for each gene 
model of a gene we stored the genomic coordinates of 
the 5′ end of the upstream intron (arrow 1 in the Figure 
S5A) and the 3′ end of the downstream intron (arrow 4) 
for each internal exons. Then, if any other gene model 
has an intron with the 5′ coordinate coinciding with the 
5′ end of the upstream intron of the gene model of inter-
est, and 3′ coordinate with the 3′ end of the downstream 
intron of the gene model of interest (arrows 5, 6), i.e. an 
intron without any annotated exon, we defined the case 
as exon-skipping events. The exon-skipping events were 
described with 4 points of genomic coordinates (arrows 
1–4), and cassette exons were described with the coordi-
nates shown with arrows 2 and 3. The events and cassette 
exons found with this algorithm were called “annotated 
exon-skipping events” and “annotated cassette exons” in 
this study, respectively.
Splicing change assessment and percent inclusion 
calculation
To assess splicing change, we obtained the expression 
of the three junctions in triplets of exons and calculated 
the percent spliced in (PSI, ψ) levels [32] as shown in 
Additional file 12: Figure S5B. Then in each replicates we 
subtracted the DMSO ψ values from the TG003 ψ val-
ues to obtain the difference in ψ values (ΔψTG003_treatment; 
Δψ = ψTG003.rep.n − ψDMSO.rep.n). To evaluate the distribu-
tion of Δψ values, we calculated the difference between 
the ψ values of the replicates of the same condition as 
a reference of baseline fluctuation (Δψbetween_replicates   
= ψDMSO.rep.2 − ψDMSO.rep.1 and ψTG003.rep.2 − ψTG003.rep.1) 
used in Fig. 1b.
Homologous exon definition
The homologous exon pairs of the following two sets 
were defined. One is human annotated cassette exons 
against mouse annotated cassette exons, and the other 
is human annotated cassette exons against all mouse 
internal exons. We obtained the Ensembl IDs for the 
genes with the human annotated exon-skipping events 
and converted them to NCBI IDs and obtained the 
numbered homologene group IDs, which were linked to 
Gene Symbol [33]. We used homologene ID as a key to 
link the human gene with the mouse homologous gene. 
Then for each comparison we used BLAST [34] to align 
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with the annotated cassette exons in the homologous 
gene of the human exon’s mouse homologous gene for 
the first set and all exons of the said gene for the sec-
ond set. After blast (-p blastn) alignment, we selected 
the homologous exon based on their sequence identity 
given by BLAST and coverage calculated by dividing the 
length of the aligned segment by the human and mouse 
exon length, respectively. We selected exons with per-
cent identity >70 % and human and mouse coverage >0.9, 
respectively. Then we mapped back the Ensembl IDs to 
its genomic coordinates and selected mouse homologous 
exons with the highest percent identity and sum of the 
two coverages. In this study, we compared not only the 
homologous cassette exons but also the flanking introns. 
For human exons we retrieved the flanking exons, which 
define the flanking introns, specified by the Ensembl IDs 
we started with. For mouse exons, when BLAST search 
identified exons which had multiple flanking exons in the 
annotation we obtained flanking exons information based 
on the exons defined as homologous with human cas-
sette exons. If Ensembl gene sets contained several sets of 
flanking exons, we chose the one with highest total junc-
tion reads expression across all samples. We note that the 
same mouse exon is possibly assigned as a homologous 
exon against multiple human cassette exons, due to exon/
gene duplication events during the evolution, or due to 
alternative 5′ splice sites or 3′ splice sites unique to the 
human species.
Sequence feature characterization
We scored six splice signals that are important for exon 
recognition, which are shown in Additional file 12: Figure 
S5C. Scoring of 5′ splice site and 3′ splice site was done 
by inputting 9-mer sequence of 5′ splice site, and 23-mer 
sequence of 3′ splice site in the software MaxEntScan 
[35]. Scoring of exonic splicing enhancers and silencers 
were based on the database SpliceAid [36]. We took all 
the binding motifs for each splicing factors registered 
in SpliceAid, and looked for its presence in each exon. 
Because we searched binding sites within the exonic 
regions, we treated binding sites with positive scores in 
the SpliceAid database as ESEs and, ones with negative 
scores as ESSs. We separately added up the number of 
ESEs and ESSs for each exon. For the branch sequence 
scores and polypyrimidine tract scores, we used SVM-BP 
finder [37]. We used 100 nucleotides of upstream introns 
as the input and predicted the branch point. We used 
human scoring system for the analysis of both species in 
order to avoid score variances for the same sequences in 
different species. When multiple branch points were pre-
dicted, we retrieved the prediction of the highest svm_scr 
and obtained the polypyrimidine tract score and branch 
sequence score from that prediction.
The control set was constructed in the following way. 
We first obtained exons from the annotated alternative 
exons in human with Δψ  =  0 in both replicates, and 
identified their mouse homologous exons from the set of 
all mouse internal exons as described in the previous sec-
tion. Then we selected mouse exons which had Δψ = 0. 
The size of the sets described in the figure legends. The 
nonparametric Wilcoxon rank sum test was used in order 
to compare the human and mouse homologous exon sets.
Enrichment analysis
We obtained 20,897 expressed annotated exon-skipping 
event set among the total of 37,497 annotated alterna-
tive splicing events. Some events were excluded because 
SVM-BP could not predict any branch points and no 
scores were calculated. We grouped the 20,897 exon-
skipping events in 48 groups depending on their exon 
length (0–64 nt, 65 nt), number of ESEs (0–4, 5–15, 
16), number of ESSs (1–19, 20), and polypyrimidine 
tract score (0–9, 10–19, 10–29, 30). We counted the 
total number of members of each group and the num-
ber of the 110 skip-enhanced (Δψ ≤ −0.25) exons cat-
egorized into this group. A minimum of 3 strongly 
skip-enhanced exons per group was required to proceed 
into the enrichment analysis. We calculated the enrich-
ment by dividing the number of strongly skip-enhanced 
exons by the total number of members of the group, and 
then dividing this by 0.00526, the average fraction of 
strongly skip-enhanced exons in random categorization 
(110/20,897 = 0.00526). Hypergeometric tests were per-
formed to calculate the enrichment p values.
Additional files
Additional file 1: Table S1. Summary of RNA-seq data. Total mapped 
reads and mapping rates are indicated for all samples used in this study.
Additional file 2: Figure S1. A RNA-seq data visualization of CLK1 exon 
4 in both human and mouse.RNA-seq data was visualized by sashimi-plot. 
Numbers of junction reads shown are calculated by our method. B Experi-
mental validation by RT-PCR.
Additional file 3: Table S2. Comparison of Δψ values of 45 TG003 skip-
enhanced human exons and their homologous mouse exons. Ensembl 
IDs and all information used to identify and classify mouse exons that 
correspond to human skip-enhanced exons (Δψ ≤ 0.05) are provided 
with in this table.
Additional file 4: Figure S2. A Experimental validation of RNA-seq data 
of different groups.RT-PCR of two exon pairs that are both skip-enhanced 
by TG003 and one pair of human TG003 skip-enhanced and mouse insen-
sitive exons. B Graphs show the RNA-seq derived ψ values.
Additional file 5: Table S3. Exon feature scores of all 21 human TG003 
skip-enhanced exons and mouse insensitive exons. Ensembl IDs, genomic 
coordinates and all information used to draw Figure 5 box plots (column 3 
and 4) are provided with in this table.
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